新生血管性年龄相关性黄斑变性的治疗需求：一项基于波兰国家登记处的研究
The Need for Treatment of Neovascular Age-Related Macular Degeneration: A Study Based on the Polish National Registry.
作者信息
Teper Sławomir Jan, Nowińska Anna, Figurska Małgorzata, Rękas Marek, Wylęgała Edward
机构信息
Chair and Clinical Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Okregowy Szpital Kolejowy w Katowicach, Panewnicka 65, 40-760, Katowice, Poland.
Department of Ophthalmology, Military Institute of Medicine, Central Clinical Hospital of the Ministry of National Defense, Warsaw, Poland.
出版信息
Ophthalmol Ther. 2022 Oct;11(5):1805-1816. doi: 10.1007/s40123-022-00545-4. Epub 2022 Jul 24.
INTRODUCTION
The Polish National AMD Therapeutic Program offered us a unique opportunity to determine the need for treatment of neovascular age-related macular degeneration (nAMD).
METHODS
A search, extraction, and analysis of data from the monitoring system of the Therapeutic Program of the National Health Fund was performed. Demographic data from the Central Statistical Office were also obtained and analyzed. All national data, and from the Silesian Voivodeship specifically, from patients who had received treatment prior to January 14, 2022 (57,876 eyes) were analyzed.
RESULTS
Approximately 0.1% of the Polish population requires treatment for nAMD when the best-corrected visual acuity (BCVA) criteria exclude irreversible severe changes in the fovea (0.2-0.8 by Snellen). There were 30,771 eyes in the therapeutic program in January 2022, and 4898 (15.9%) of them were in Silesia, which contains 11.7% of the total population and 12.4% of the elderly population (65 years of age and older). However, as a result of the COVID-19 pandemic, the average number of monthly enrollments in the therapeutic program decreased from 717 in the first quarter of 2020 to 505 in the second quarter (with a low of 407 in April). Moreover, in 2020, a negative balance was recorded between included and excluded patients.
CONCLUSION
The need for nAMD treatment in the elderly community (65 years of age and older) is estimated to be 0.55-0.66%.
引言
波兰国家年龄相关性黄斑变性（AMD）治疗项目为我们提供了一个独特的机会，以确定新生血管性年龄相关性黄斑变性（nAMD）的治疗需求。
方法
对国家卫生基金治疗项目监测系统的数据进行了检索、提取和分析。还获取并分析了中央统计局的人口数据。对所有国家数据，特别是来自西里西亚省，在2022年1月14日前接受治疗的患者（57,876只眼）的数据进行了分析。
结果
当最佳矫正视力（BCVA）标准排除黄斑中心凹不可逆的严重变化（Snellen视力表0.2 - 0.8）时，波兰约0.1%的人口需要nAMD治疗。2022年1月治疗项目中有30,771只眼，其中4898只眼（15.9%）在西里西亚省，该省人口占全国总人口的11.7%，老年人口（65岁及以上）占12.4%。然而，由于新冠疫情，治疗项目的月平均入组人数从2020年第一季度的717人降至第二季度的505人（4月最低降至407人）。此外，2020年纳入和排除患者之间出现了负平衡。
结论
老年群体（65岁及以上）中nAMD的治疗需求估计为0.55 - 0.66%。
Zotero 插件